• Publications
  • Influence
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
TLDR
The association of the IL28B locus with natural and treatment-associated control of HCV indicates the importance of innate immunity and interferon lambda in the pathogenesis ofHCV infection. Expand
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
TLDR
Among patients with chronic HCV infection and advanced hepatic fibrosis, sustained virological response to interferon-based treatment was associated with lower all-cause mortality. Expand
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
TLDR
The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data. Expand
Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
TLDR
It is suggested that PNPLA3 genotyping has the potential to contribute to multi-factorial patient-risk stratification, identifying those to whom HCC surveillance may be targeted. Expand
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
TLDR
An open-label study assessing the safety and efficacy of ledipasvir, sofosbuvir, and ribavirin in patients with HCV genotype 1 or 4 and advanced liver disease found high rates of sustained virological response 12 weeks after treatment. Expand
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
TLDR
It is confirmed that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN. Expand
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
TLDR
The present report summarizes the proposal of the expert panel: four substages of intermediate HCC patients, B1 to B4, to tailor therapeutic interventions based on the evidence available to date and expert opinion. Expand
Angiogenesis and hepatocellular carcinoma.
TLDR
A Phase I clinical trial of intratumoral injection of adenovirus encoding interleukin-12 in patients with hepatocellular carcinoma and other advanced gastrointestinal tumors shows antimetastatic activity using a hepato cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Expand
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
TLDR
Results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH show clinically significant histological improvement that is reasonably likely to predict clinical benefit. Expand
Total tumor volume and alpha‐fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation
TLDR
An increased risk of dropout on the waiting list can be expected, but with equivalent and satisfactory post‐transplant survival in centers with at least 8‐month waiting time. Expand
...
1
2
3
4
5
...